EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer

Kumiko Nishio, Lise Pasquet, Kaddy Camara, Julia DiSapio, Kevin S Hsu, Shingo Kato, Anja Bloom, Stewart K Richardson, Joshua A Welsh, Tianbo Jiang, Jennifer C Jones, Susanna Cardell und 5 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci165281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Kumiko Nishio und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Branch, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Natural Killer T-Cells, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI/NIH, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a structure-function study of sulfatides that typically stimulate type II NKT cells, we made an unexpected discovery. We compared analogs with sphingosine or phytosphingosine chains and 24-carbon acyl chains with 0-1-2 double bonds (C or pC24:0, 24:1, or 24:2). C24:1 and C24:2 sulfatide presented by the CD1d monomer on plastic stimulated type II, not type I, NKT cell hybridomas, as expected. Unexpectedly, when presented by bone marrow-derived DCs (BMDCs), C24:2 reversed specificity to stimulate type I, not type II, NKT cell hybridomas, mimicking the corresponding β-galactosylceramide (βGalCer) without sulfate. C24:2 induced IFN-γ-dependent immunoprotection against CT26 colon cancer lung metastases, skewed the cytokine profile, and activated conventional DC subset 1 cells (cDC1s). This was abrogated by blocking lysosomal processing with bafilomycin A1, or by sulfite blocking of arylsulfatase or deletion of this enyzme that cleaves off sulfate. Thus, C24:2 was unexpectedly processed in BMDCs from a type II to a type I NKT cell-stimulating ligand, promoting tumor immunity. We believe this is the first discovery showing that antigen processing of glycosylceramides alters the specificity for the target cell, reversing the glycolipid's function from stimulating type II NKT cells to stimulating type I NKT cells, thereby introducing protective functional activity in cancer. We also believe our study uncovers a new role for antigen processing that does not involve MHC loading but rather alteration of which type of cell is responding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Natural Killer T-CellsNeoplasmsHumansSulfoglycosphingolipidsAntigens, CD1dAntigen PresentationSulfates

Stichwörter der Autor:innen

Antigen processingCell BiologyCellular immune responseImmunologyTumor suppressors

Substanzen

SulfoglycosphingolipidsAntigens, CD1dSulfates

Autor:innen und Institutionen

  • Vaccine Branch, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
  • Department of Chemistry, University of Connecticut, Storrs, Connecticut, USA.
  • Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  • Department of Immunology and Stem Cell Biology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
  • Neuro-Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA.

Förderung

  • NIGMS NIH HHS
  • NCI/NIH
  • NIH

Zitieren

APA

Nishio, K., Pasquet, L., Camara, K., DiSapio, J., Hsu, K. S., Kato, S., Bloom, A., Richardson, S. K., Welsh, J. A., Jiang, T., Jones, J. C., Cardell, S., Watarai, H., Terabe, M., Olkhanud, P. B., Howell, A. R., & Berzofsky, J. A. (2024). Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci165281

Vancouver

Nishio K, Pasquet L, Camara K, DiSapio J, Hsu KS, Kato S, et al. Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. Journal of Clinical Investigation. 2024. doi:10.1172/jci165281

BibTeX
@article{Nishio2024,
  author = {Nishio, Kumiko and Pasquet, Lise and Camara, Kaddy and DiSapio, Julia and Hsu, Kevin S and Kato, Shingo and Bloom, Anja and Richardson, Stewart K and Welsh, Joshua A and Jiang, Tianbo and Jones, Jennifer C and Cardell, Susanna and Watarai, Hiroshi and Terabe, Masaki and Olkhanud, Purevdorj B and Howell, Amy R and Berzofsky, Jay A},
  title = {Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci165281}
}
Kostenlos starten →